VectivBio ( NASDAQ:VECT – Get Rating ) was downgraded by research analysts at Credit Suisse Group from an 'outperform' rating to a 'neutral' rating in a report released on Monday, The Fly reports. Separately, Piper Sandler upped their price objective on VectivBio from $23.00 to $25.00 and gave the company an 'overweight' rating in a research note on Thursday, April 20th. NASDAQ VECT traded up $4.31 on Monday, reaching $16.21. The company had a trading volume of 23,488,752 shares, compared to its average volume of 279,017.

https://www.dailypolitical.com/2023/05/22/vectivbio-nasdaqvect-downgraded-by-credit-suisse-group.html

#dailypolitical